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PURPOSE. In ischemic proliferative retinopathies, Mu¨ller glial cells (MGCs) acquire migratory
abilities. However, the mechanisms that regulate this migration remain poorly understood. In
addition, proliferative disorders associated with enhanced activities of matrix metal-
loproteinases (MMPs) also involve insulin-like growth factor (IGF)-1 participation. Therefore,
the main interest of this work was to investigate the IGF-1 effect on the extracellular
proteolytic activity in MGCs.
METHODS. Cell culture supernatants and cell lysates of the human MGC line MIO-M1
stimulated with IGF-1 were analyzed for MMP-2 by zymographic and Western blot analysis.
The MGCs’ motility was evaluated by scratch wound assay. The MMP-2, b1-integrin, and focal
adhesions were detected by confocal microscopy. The localization of active MMPs and actin
cytoskeleton were evaluated by in situ zymography.
RESULTS. The IGF-1 induced the activation of canonical signaling pathways through the IGF-1R
phosphorylation. Culture supernatants showed a relative decrease in the active form of MMP-
2, correlating with an increased accumulation of MMP-2 protein in the MGCs’ lysate. The IGF-
1 effect on MMP-2 was abolished by an IGF-1R blocking antibody, aIR3, as well as by the PI3-
kinase inhibitor, LY294002. The IGF-1 increased the migratory capacity of MGCs, which was
blocked by the GM6001 MMP inhibitor, LY294002 and aIR3. Finally, IGF-1 induced the
intracellular distribution of MMP-2 toward cellular protrusions and the partial colocalization
with b1-integrin and phospo-focal adhesion kinase signals. Gelatinase activity was
concentrated along F-actin filaments.
CONCLUSIONS. Taken together, these data indicate that IGF-1, through its receptor activation,
regulates MGCs’ motility by a mechanism that involves the MMP-2 and PI3K signaling
pathway.
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Insulin-like growth factor 1 (IGF-1) is a 70–amino acid peptidebelonging to a family of polypeptide trophic factors with
mitogenic, differentiating, antiapoptotic, and metabolic func-
tions.1 These biological actions are mediated by the IGF-1
receptor (IGF-1R), a member of the tyrosine kinase gene family
of growth factor receptors.2 Upon IGF-1 binding, the activated
IGF-1R promotes phosphorylation of specific cytosolic sub-
strates, then the IGF-1 signal is transmitted to two downstream
pathways: extracellular signal–regulated kinases 1 and 2 (ERK
1/2) and phosphatidylinositol 3-kinase (PI3K/AKT).1 Circulat-
ing IGF-1 is mainly released from the liver in response to
pituitary growth hormone; however, a number of other tissues
can also produce IGF-1 locally, including the central nervous
system (CNS).3–5 Despite its peripheral location, the retina is
part of the CNS, and there is considerable evidence that IGF-1 is
important for neural and vascular retinal development.6,7 In
addition, the IGF-1/IGF-1R system has also been implicated in
retinopathies, and an increasing of IGF-1 levels has been found
in vitreous samples from patients with proliferative diabetic
retinopathy (PDR),8–10 whereas its participation in retinopathy
of prematurity (ROP) appears to be more complex.11
Mu¨ller glial cells (MGCs) are the main glial cell type in the
retina. They constitute an anatomic and functional link
between retinal neurons and compartments to exchange
molecules and play a crucial role in supporting neuronal
development, survival, and information processing.12–15 The
MGCs are also involved in the production and secretion of
growth factors, including IGF-1.16,17 In pathologic conditions,
such as PDR and proliferative vitreoretinopathy (PVR),18 MGCs
adopt a number of drastic changes at the level of gene and
protein expression, which impact on their morphology,
migration, and proliferation, followed by extracellular matrix
(ECM) degradation. This results in the formation of retinal
membranes and resembles physiological processes of wound
healing and fibrosis.19–21 Both metalloproteinase (MMP)-2 and
MMP-9 have been associated with these processes, and MGCs
are one type of MMP-producing cells in the retina.22,23 During
proliferative retinopathy, MGCs encounter different ECM
proteins, cytokines, and growth factors because these are often
present in the vitreous humor and retinal tissues of affected
eyes.24–27 Therefore, MGCs’ functions, including the produc-
tion or regulation of matrix-degrading enzymes, may be
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influenced by cytokines and growth factors present in the
retinal microenvironment. Whereas the MMP-9 expression was
increased in MGCs stimulated by TNF-a,22 we previously
demonstrated that a2-macroglobulin (a2M), an acute-phase
response protein involved in retinopathies, induces MMP-2
activation and regulates membrane type 1 MMP (MT1-MMP)
activity.28
Studies in models of CNS injury have demonstrated that the
IGF-1/IGF-1R system stimulates cell migration of oligodendro-
cytes,29 astrocytes,30 and neuronal cells.31 However, there is
no information about the IGF-1 effect on MGCs’ migration in
retinopathies. The evidence accumulated over the past three
decades has demonstrated that the IGF-1 system plays an
important role as a regulator of tumor cell invasion by
modulating the MMP-2 synthesis and activity.32,33 Like other
members of the MMP family, MMP-2 synthesis and function are
regulated at multiple levels, including transcriptional activa-
tion, posttranscriptional processing, regulation of proteolytic
activity by MT1-MMP, and inhibition through the tissue
inhibitors of MMP (TIMP).34
MMP-2 is constitutively expressed and secreted in a latent
form or pro-MMP-2 (72 kDa). Its activation to MMP-2 takes
place at the cell surface and requires the participation of the
active form of MT1-MMP that binds pro-MMP-2 on the cell
membrane in a multimeric complex with TIMP-2.35 Enhanced
expression or activity of MMP-2 was previously reported
within retinal neovascular tissue, as well as in vitreous or
aqueous samples from patients with PDR,36 suggesting that
MMP-2 is an important therapeutic target in retinopathies. On
the other hand, serum MMP-2 levels in these same diabetic
patients were almost identical to control patients, indicating
that increased levels of MMP-2 in the eyes were an ocular and
not systemic consequence. In addition, numerous studies have
reported high levels of IGF-1 in vitreous fluid of diabetic
patients.8,9,37 However, the precise role of IGF-1 in the
pathogenesis of retinopathies remains unclear. Our hypothesis
is that IGF-1 plays a major role on the extracellular MMP-2
activity and cellular motility of MGCs during retinal ischemic
proliferative disease. Thus, in the present study we investigated
the IGF-1 effect on MMP-2 activity and cell migration in a well-
characterized MGC line, MIO-M1.
MATERIALS AND METHODS
A spontaneously immortalized human MGC line (MIO-M1),
kindly provided by G. Astrid Limb (UCL Institute of Ophthal-
mology and Moorfields Eye Hospital, London, UK), was used.38
Cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen, Buenos Aires, Argentina) containing 4500
mg/L glucose, sodium pyruvate) with 2 mM L-glutamine
(GlutaMAX; Invitrogen), 10% vol/vol fetal bovine serum, and
50 U/mL penicillin/streptomycin (Invitrogen) at 378C with 5%
CO2. Recombinant human IGF-1 was purchased from Sigma-
Aldrich Corp. (St. Louis, MO, USA). Immunoblots were
performed with the following primary monoclonal antibodies:
anti-phosphorylated ERK 1/2 (anti-p-ERK 1/2), polyclonal
rabbit anti-total ERK 1/2, anti-calreticulin, and anti-MMP-2
(specific for the active form), all from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA, USA). Rabbit monoclonal anti-
phospho-IGF-1R antibody was obtained from Cell Signaling
Technologies, Inc. (Danvers, MA, USA). Mouse monoclonal
anti-IGF-1R and MT1-MMP antibodies were both from Abcam,
Inc. (Cambridge, MA, USA). Secondary antibodies used for
immunoblotting were horseradish peroxidase–conjugated
streptavidin (Thermo Fisher Scientific, Rockford, IL, USA).
Dilutions for primary antibodies were between 1/250 and 1/
1000, whereas for secondary antibodies they were 1/5000. To
block IGF-1/IGF-1R binding, cells were pretreated with a
mouse monoclonal antibody specific against the IGF-1 recep-
tor, aIR3 (Calbiochem, San Diego, CA, USA), at a final
concentration of 16 nM. The inhibitory studies of ligand
signaling included ERK 1/2 inhibitor PD-98059 and PI3K
inhibitor LY-294002, both from Sigma-Aldrich Corp. Collagen
type I (Col-I) or laminin used in the wound healing assays were
also from Sigma-Aldrich Corp. To inhibit cell proliferation,
hydroxyurea was used (Sigma-Aldrich Corp.). To block MMPs, a
hydroxamate-based inhibitor N-[(2R)-2(hydroxamideocarbonyl-
methyl)-4-methylpantanoyl]-L-tryptophan methylamide]
(GM6001) was obtained (Calbiochem). To visualize cellular
localization of proteins, we used two different monoclonal
antibodies against MMP-2 (mouse anti-MMP-2 or rabbit anti-
MMP-2): a rabbit anti-b1-integrin antibody (Abcam, Inc.,
Cambridge, MA, USA) and a mouse anti-phospo-focal adhesion
kinase (p-FAK) antibody (Santa Cruz Biotechnology, Inc.).
Secondary antibodies were raised in goat against rabbit or
mouse IgG conjugated with Alexa Fluor 488 and 594,
respectively (Molecular Probes, Eugene, OR, USA). The FITC-
labeled DQ-collagen and Alexa Fluor 594 phalloidin, used in an
in situ zymography assay and in actin cytoskeleton labeling,
were also purchased from Molecular Probes.
Western Blot Assay
To evaluate the IGF-1 effect on IGF-1R autophosphorylation
and to investigate the involvement of the classical signaling
pathways, MIO-M1 cells were plated in the presence or
absence of IGF-1 (10 nM) for different periods of times. To
evaluate the MMP-2 and MT1-MMP expression, MIO-M1 cells
were incubated with IGF-1 (10 nM) for up to 8 hours. At the
end of each treatment, cells at 70% to 80% confluence were
kept on ice, and the medium was aspirated and lysed using
nondenaturalizing buffer (20 mM Tris-HCl, 1% Triton X-100,
10% glycerol, 137 mM ClNa, 0.01% wt/vol bromophenol
blue) containing phenyl methyl sulfonyl fluoride (1 mM),
sodium orthovanadate (10 mM), and a protease inhibitor
cocktail (Sigma-Aldrich Corp.). Protein concentrations were
determined with a BCA protein assay kit (Pierce, Buenos
Aires, Argentina) using albumin as standard. Aliquots
containing proteins (50 lm) were resolved on 10% SDS-
PAGE and transferred onto nitrocellulose membranes
(Amersham Hybond ECL; GE Healthcare Bio-Sciences AB,
Uppsala, Sweden). Nonspecific binding was blocked with
5% bovine serum albumin (BSA) in Tris-buffered salt
containing 0.01% Tween-20, and the same solution was
used to prepare primary antibodies, which were incubated
with the membranes overnight at 48C. Membranes were
incubated with a peroxidase-conjugated secondary antibody
for 1 hour at room temperature (RT). Finally, the specific
bands were revealed using a chemiluminescence kit
(Thermo Fisher Scientific) and quantified by densitometric
analysis using analysis software (Gel Pro Analyzer; Media
Cybernetics, Inc., Rockville, MD, USA).
Gelatin Zymography Assays
Standard methodology for gelatin zymography was used to
detect MMPs gelatinolytic activity in MIO-M1 cell supernatants
as described previously by Kleiner and colleague.39 For this
purpose, MIO-M1 cells (5 3 105 cells/well) were cultured at
378C for 24 hours. The cells were then rinsed twice with
serum-free medium, and 1 mL of DMEM-high glucose was
added. Cells were stimulated with 10 nM IGF-1 at different
times (4–8 hours), after which the cell culture supernatants
were collected. To block IGF-1/IGF-1R binding, cells were
previously pretreated with aIR3 in serum-free medium for 30
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minutes before ligand addition. Capillary blood was used as a
positive control of MMP gelatinolytic activity. Aliquots of 30 lL
cell supernatants were resolved on 10% SDS-PAGE/1.5% gelatin
(Sigma-Aldrich Corp.) in denaturing and nonreducing condi-
tions. Gels were soaked for 1 hour with 2.5% Triton X-100 to
remove the SDS, and the MMP activity was developed at 378C
in the enzyme buffer (50 mM Tris-HCl, 0.2 M NaCl, and 5 mM
CaCl2, pH 7.5) for 24 hours. After incubation, gels were stained
for 30 minutes in 0.125% Coomassie blue R-250, and the stain
was removed with the same solution without the dye until
clear bands of gelatinolysis appeared on a dark background.
The MMP-2 and MMP-9 were identified by molecular size using
high-molecular-mass (14.5–200 kDa) standards (Bio-Rad, Her-
cules, CA, USA). Images were processed, and the intensity of
the bands was obtained using the imaging program Gel Pro
Analyzer (Media Cybernetics, Inc.).
Biotinylation Assay
A biotin-labeling protein assay using sulfo-NHS-SS-biotin (No-
Weigh EZ-Link; Thermo Fisher Scientific) was performed
following the manufacturer’s procedure. Briefly, to evaluate
MT1-MMP membrane expression, MIO-M1 cells were stimu-
lated with IGF-1 (8 hours), washed with PBS, and incubated
with sulfo-NHS-SS-biotin for 1 hour at 48C. After biotin
incubation, cells were again washed and lysed with PBS
0.2% Triton X-100 containing a protease cocktail inhibitor.
Then 5 lL of 20% agarose-streptavidin beads were incubated
with the lysates (100 lg) for 2 hours at RT. When the
incubation was finished, the lysates were removed, the beads
washed with PBS, and the bound proteins eluted. Equal
amounts of eluted proteins were resolved on SDS-PAGE and
blotted with an anti-MT1-MMP antibody. Results were
quantified by ImageJ software (http://imagej.nih.gov/ij/;
provided in the public domain by the National Institutes of
Health, Bethesda, MD, USA).
Cell Migration Assays
Cell migration activities were examined by a two-dimension-
al scratch wound assay in six-well plates coated with Col-I
(10 lg/cm2) or laminin (1 lg/cm2; Sigma-Aldrich Corp.). The
MIO-M1 cells (53105 cells/well) were cultured for 24 hours.
In each well, a straight lesion was created in the center of
the MIO-M1 cell monolayer with a sterile 10-lL pipette tip.
This technique produced a consistent wound devoid of cells,
~35 mm long3 400 lm wide. Wells were then rinsed twice
with serum-free medium to remove any cell debris, and 2 mL
of DMEM-high glucose without red phenol was added. Cells
were treated with 10 nM IGF-1 for 12 hours. To block IGF-1/
IGF-1R binding, cells were pretreated with aIR3 for 30
minutes. In another set of experiments, to inhibit MMPs
activity, cells were preincubated with GM6001 MMP
inhibitor (20 nM) for 30 minutes.28 In addition, to inhibit
the activity of PI3K, cells were also pretreated with LY-
294002. In all the migration experiments and to inhibit cell
proliferation, cells were preincubated with 0.5 mM hydroxy-
urea.
Cellular migration was measured following a procedure
previously described.28 Briefly, at selected times (0 and 12
hours), three random images of the wound per condition were
acquired using a charge-coupled device camera (Nikon; Nikon,
Inc., Melville, NY, USA) using bright-field microscopy (inverted
microscope Nikon TU-2000; Nikon, Inc.) with a 103 objective
(0.3 numerical aperture). Each image defined an average area
of the wound equivalent to 53 105 6 13 104 lm2 recorded to
t ¼ 0 hours. Cells invading this area were counted to t ¼ 12
hours and results expressed as cells per area.
Immunofluorescence Labeling and Confocal
Microscopy
To evaluate the cell distribution of MMP-2, b1-integrin, and p-
FAK, MIO-M1 cells were grown to 30% to 70% confluence on
glass coverslips coated with Col-I (10 lg/cm2) in 24-well plates
before being stimulated, or not, with IGF-1 (10 nM) for 8 hours.
Coverslips containing the cells were washed twice with PBS,
fixed in 4% paraformaldehyde (PFA) for 15 minutes at RT,
permeabilized with 0.1% (vol/vol) Triton X-100, and blocked
with 2% BSA for 1 hour at 378C to block nonspecific binding
sites. The coverslips were then incubated overnight at 48C
with primary antibodies diluted 1:50, washed three times with
PBS plus 1% BSA, and exposed to secondary antibodies diluted
1:800 for 45 minutes at RT. After a thorough rinse with PBS
plus 1% BSA, cell nuclei were stained at 1:1000 dilution
(Hoechst no. 33258; Molecular Probes). Cells were washed
with PBS and mounted on glass slides with reagent (Mowiol 4-
88, Calbiochem; Merck KGaA, Darmstadt, Germany). Fluores-
cent images were obtained with a confocal laser-scanning
biological microscope (Olympus FluoView FV1000; Olympus
Corp., New York, NY, USA). Finally, images were processed
with microscope software (FV10-ASW Viewer 3.1; Olympus
Corp.) and with ImageJ software.
In Situ Zymography
To localize net pericellular proteolysis in MGCs, we used an in
situ zymography assay described by Rivera.40 Briefly, after 12
hours of IGF-1 stimulus, migrating MGCs were rinsed in PBS
and media was replaced by fresh media containing serum-free
DMEM supplemented with calcium (5 mM CaCl2 in 50 mM
Tris, pH 7.6) and 100 lg/mL of FITC-labeled DQ-collagen that is
intramolecularly quenched. Cells were incubated for 6 hours in
a dark, humid chamber at 378C, rinsed in PBS, fixed in 4% PFA/
sucrose, and permeabilized with 0.1% (vol/vol) Triton X-100.
For actin cytoskeleton labeling, nonspecific binding was
blocked with 2% BSA for 1 hour at 378C. Cells were then
incubated with Alexa Fluor 594 phalloidin, rinsed in PBS plus
1% BSA, and incubated with Hoechst no. 33258 (1:1000
dilution). Finally, cells were mounted on glass slides with
Mowiol 4-88 reagent. Collagen-FITC cleavage by cellular
proteinases releases quenched fluorescence representative of
net proteolytic activity. Cells incubated without DQ-collagen
were not fluorescent.
Statistical Methods
For the densitometric quantifications and cellular migration
assays, results were expressed as the mean plus or minus
standard deviation of independent experiments; one-way
ANOVA and a Tukey comparison posttest were used. For
microscope quantifications of the level of colocalization, a
JACoP plugin from ImageJ software was used.41 At least 50
cells per condition were analyzed. Differences from the control
were considered significant at P < 0.05.
RESULTS
IGF-1 Induces IGF-1R Phosphorylation and
Intracellular Signaling Activation in MIO-M1 Cells
To investigate the effect of IGF-1 on the intracellular signaling
pathways activation in MGCs, we used the MIO-M1 cell line,
which constitutively expresses IGF-1R (Lorenc VE, et al. IOVS
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2010;51:ARVO E-Abstract 5760; this study). Upon stimulation
with IGF-1 (10 nM) for different periods of time (1, 5, 10, and
20 minutes), we clearly demonstrated by Western blot assays a
time-dependent increase at the tyrosine phosphorylation of the
98-kDa IGF-1R b-subunit without an evident modification of
the IGF-1R protein expression (Fig. 1A). In this period, the AKT
and ERK 1/2 phosphorylation were also observed (Figs. 1B,
1C). The quantitative analysis revealed a significant increase of
AKT phosphorylation from 5 minutes of IGF-1 treatment,
whereas p-ERK 1/2 level was significant from 10 minutes of
IGF-1 stimulation. These results indicate that the binding of
IGF-1 to IGF-1R on MIO-M1 cells induced activation of both
signaling pathways.
To demonstrate whether the IGF-1R phosphorylation and
subsequent activation of PI3K/AKT and MAPK/ERK 1/2
pathways in MIO-M1 cells were specific responses to the
IGF-1 binding to its receptor, we used a blocking antibody,
aIR3, which specifically binds to the extracellular subunits of
the IGF-1R.42 The pretreatment of MIO-M1 cells with aIR3 for
30 minutes completely inhibited both IGF-1R and AKT
phosphorylation induced by IGF-1 stimulation, while the levels
of p-ERK 1/2 returned to control level (Fig. 1D). The
preincubation of aIR3 alone did not produce any change in
the phosphorylation levels of all molecules examined (Fig. 1D).
In addition, AKT and ERK 1/2 phosphorylation induced by IGF-
1 were fully inhibited in the presence of LY-294002, a specific
PI3K inhibitor, and PD980059, a Mek 1/2 inhibitor (data not
shown).
IGF-1 Regulates the Extracellular Levels of MMP-2
in MIO-M1 Cells
In order to analyze the effect of IGF-1 on the extracellular
levels of MMP-2 and MMP-9 secreted by MGCs, MIO-M1 cells
were stimulated with IGF-1 (10 nM) for different periods of
time (4, 6, and 8 hours), and cell culture supernatants were
analyzed by gelatin zymography assays. IGF-1-untreated
MIO-M1 cells showed a constitutive expression of the pro-
form of MMP-2 (72 kDa) together with a minor presence of
the active form (62 kDa), which was well evidenced at 6 and
8 hours of cell culture, compared with untreated cells (Fig.
2A). In these experimental conditions, pro- and active forms
of MMP-9 were undetectable and unaffected by the
presence of IGF-1 (Fig. 2A). Then, to examine whether the
effect of IGF-1 on the extracellular levels of MMP-2 active
form was mediated by IGF-1R, MIO-M1 cells were cultured
in the presence of aIR3 antibody. The preincubation of MIO-
M1 cells with blocking antibody abolished the IGF-1 effect
on active MMP-2 without affecting the extracellular levels of
pro-MMP-2 (Fig. 2B). Finally, to investigate whether IGF-1-
induced signaling pathways play any role on the extracel-
lular levels of the active form of MMP-2 in MIO-M1 cells, PD-
98059 (20 lM) and LY-294002 (10 lM) were used. The
zymographic results showed that the preincubation of MIO-
M1 cells with LY-294002 restored the presence of the active
MMP-2 in cell supernatants of MIO-M1 cells treated with
IGF-1 (Fig. 2C). On the other hand, the pretreatment of the
MIO-M1 cells with PD-980059 (Fig. 2C) did not produce
significant changes in the MMP-2 activity, indicating that the
PI3K/AKT but not MAPK/ERK 1/2 pathway is involved in
the IGF-1 effect on the extracellular levels of active MMP-2.
Phospho-specific antibodies to ERK 1/2 or AKT confirmed
that, at the concentrations used, PD-98059 did not affect
AKT phosphorylation and LY-294002 did not affect MAPK-
ERK 1/2 signaling (data not shown).
IGF-1 Produces Cell Lysate Accumulation of MMP-2
Without Modifying the Cell Surface Expression of
MT1-MMP in MIO-M1 Cells
Considering the zymographic results obtained above, we
decided to analyze the presence of MMP-2 protein in cell
lysates and culture supernatants by Western blot assays, using a
monoclonal antibody that specifically recognizes the active
form of this MMP, in MIO-M1 cells incubated with IGF-1. Figure
3 shows that the active MMP-2 (62 kDa) was only detected in
culture supernatants of nonstimulated MIO-M1 cells for 8
hours, whereas under IGF-1 treatment active MMP-2 was
undetectable during this time. However, the nondetection of
active MMP-2 in supernatants of nonstimulated MIO-M1 cells
for 4 and 6 hours may be due to the low concentration of this
isoform, which was undetectable by the Western blot assay. By
contrast, the analysis of cell lysates showed that active MMP-2
was detected in MIO-M1 cells treated with IGF-1 for 6 and 8
hours but not in nonstimulated cells. These results suggest that
IGF-1 induces the cell surface anchoring of active MMP-2
together with a significant decrease at the extracellular level.
Since the pro-form of MMP-2 is converted to the active form
on the cell surface by MT1-MMP,43,44 we also analyzed the MT1-
MMP protein expression in MIO-M1 cells treated with IGF-1.
Western blot analysis revealed that at 8 hours of IGF-1
treatment the MT1-MMP expression increased in MIO-M1 cells
(Fig. 4A). Then, to determine whether the IGF-1 treatment
produced MT1-MMP accumulation on the cell plasma mem-
brane, a sulfo-NHS-SS-biotin–labeling cell surface protein assay
was used. To carry out the assay, MIO-M1 cells were treated
with IGF-1 for 8 hours, followed by biotin labeling, as detailed
in the Materials and Methods section. Results showed that the
amount of biotinylated MT1-MMP at cell surface level was not
modified after stimulation with IGF-1 (Fig. 4B). These results
indicate that the increase in MT1-MMP under IGF-1 stimulation
was not correlated with an enhanced presence of this
membrane protein at cell surface level, suggesting that MT1-
MMP is not involved in the decrease of the active form of MMP-
2 at the extracellular level.
IGF-1 Induces MIO-M1 Cell Migration Mediated by
Its Cognate Receptor
To determine whether IGF-1/IGF-1R system is functionally
involved in MGC migration, we used a two-dimensional scratch
wound assay where MIO-M1 cells were cultured in laminin and
Col-I-coated plates. Since we have already demonstrated by
bromodeoxyuridine assay that IGF-1 (12 hours) was able to
induce MIO-M1 cell proliferation (data not shown), these
migration assays were carried out in the presence of
hydroxyurea, a known pharmacologic inhibitor of cell
proliferation. Figure 5A shows representative scratch wound
assays of MIO-M1 cells cultured in Col-I-coated plates
stimulated or not with IGF-1 (10 nM) at the beginning (0
hours) and at the end (12 hours) of each experiment. In this
experiment it is observed that an enhanced number of cells are
invading the wound area in the presence of IGF-1 with respect
to nonstimulated cells. Bar graphs represent the quantitative
analysis of migration assays performed in laminin- and Col-I-
coated plates. In this way, results revealed that in the absence
of IGF-1 MIO-M1 cells cultured in Col-I-coated plates enhanced
the cell number invading the wound area, compared with
laminin-coated plates. However, IGF-1 significantly increased
the number of cells migrating to the wound area after 12 hours
of stimulus in both ECM proteins when compared to untreated
cells.
To examine whether the IGF-1-induced cell migration is
mediated by IGF-1R, MIO-M1 cells were previously treated with
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FIGURE 1. IGF-1 induces IGF-1R autophosphorylation and downstream activation of intracellular signaling pathways in MIO-M1 cells. (A) Western
blot analysis of phosphorylated IGF-1R (p-IGF-1R) in MIO-M1 cells cultured in the presence of 10 nM IGF-1 at indicated times. IGF-1R is shown as a
loading control. (B) Representative Western blot assay of phosphorylated AKT (p-AKT) in MIO-M1 cells cultured in the presence of 10 nM IGF-1 at
indicated times. AKT 1/2/3 is shown as a loading control. The bars represent the densitometric analysis of the immunoreactive protein expressed as
relative intensity calculated from the densitometric intensity of p-AKT signal normalized to AKT 1/2/3. Bars represent the mean 6 SD of three
independent experiments. The asterisks show statistical differences with respect to control (0 minutes) for P < 0.01 (**) and P < 0.001 (***),
respectively. (C) Representative Western blot assay of phosphorylated ERK 1/2 (p-ERK 1/2) in MIO-M1 cells cultured in the presence of 10 nM IGF-1
at indicated times. ERK 1/2 is shown as a loading control. The bars represent the densitometric analysis of the immunoreactive protein expressed as
relative intensity calculated from the densitometric intensity of p-ERK 1/2 signal normalized to ERK 1/2. Bars represent the mean 6 SD of three
independent experiments. ns, nonsignificant. The asterisks show statistical differences with respect to control (0 minutes) for P < 0.001 (***). (D)
Western blot assay of lysates from cells preincubated (or not) with the aIR3 antibody in the presence or absence of 10 nM IGF-1, showing p-IGF-1R,
p-AKT, and p-ERK 1/2 levels. IGF-1R is shown as a loading control.
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aIR3 antibody. Figure 5B shows that the pretreatment of MIO-
M1 cells with aIR3 antibody significantly blocked the effect of
IGF-1 on the cell migration, indicating that this process was
mediated by IGF-1R. Next, to evaluate the specific role of MMP-
2 in the cellular migration induced by IGF-1, MIO-M1 cells were
pretreated with GM6001, a well-established MMP inhibitor.
Interestingly, IGF-1-induced cellular migration was also signif-
icantly reduced by this inhibitor (Fig. 5B), indicating that MMP-
2 activity played a critical role in the migratory process
mediated by IGF-1. Finally, and considering that the PI3K/AKT
signaling pathway participates in the regulation of the
extracellular MMP-2 levels, we examined the IGF-1-induced
MIO-M1 migration in cells pretreated with LY294002. In this
way, a significant reduction in the cell motility to wound area
was also observed (Fig. 5B).
IGF-1 Induces the Partial Colocalization of MMP-2
With b1-integrin and p-FAK at the Cell Protrusions
Functional interactions exist between integrins and MMP-2 in
cell types with migratory phenotypes,45–47 including astro-
cytes40,48 and probably MGCs. With this in mind, by confocal
microscopy, we examined the cellular distribution of b1-
integrin and MMP-2 in nontreated and IGF-1-treated MGCs.
Figure 6A shows that in the absence of IGF-1, both b1-integrin
and MMP-2 showed a punctate perinuclear distribution with
certain fluorescence spread over the cell periphery. Under this
experimental condition, both proteins showed a low degree of
colocalization. However, under IGF-1 stimulus (8 hours), an
increased proportion of b1-integrin and MMP-2 colocalized in
the cell periphery, preferentially at the leading edge associated
with lamellipodia or cellular protrusions, without changes in
perinuclear regions with respect to nonstimulated cells. The
quantitative analysis showed that in cellular protrusions, b1-
integrin and MMP-2 signals partially colocalized (~18%) in
MIO-M1 cells cultured in the presence of IGF-1, with respect to
nonstimulated cells (~3%). By contrast, in perinuclear regions,
although b1-integrin also showed a certain level of colocaliza-
tion with MMP-2 (~18%), this proportion was not significantly
modified by IGF-1 (Fig. 6B).
FIGURE 2. IGF-1 decreases active MMP-2 levels in MIO-M1 cell
supernatants in a process mediated by IGF-1R and PI3K signaling
pathway. (A) Zymographic analysis of MIO-M1 culture supernatants
obtained from cells stimulated with IGF-1 for 4, 6, or 8 hours. The pro-
MMP-9 (92 kDa), pro-MMP-2 (72 kDa), and MMP-2 (active form; 62
kDa) are indicated. Capillary blood (SC) was used as a gelatinase
control of MMP-9 and pro-MMP-2. (B) Zymographic analysis of culture
supernatants of MIO-M1 cells pretreated with aIR3 antibody (16 nM)
for 30 minutes and then stimulated with IGF-1 for 8 hours. (C)
Zymographic analysis of culture supernatants of MIO-M1 cells
preincubated with LY-294002 (10 lM), PD98059 (20 lM), or both
pharmacologic inhibitors together, as well as aIR3 antibody, then
FIGURE 3. IGF-1 produces an accumulation of active MMP-2 in cell
lysates. Western blot assay for the determination of active MMP-2 from
lyophilized culture supernatants and cell lysates of MIO-M1 cells
cultured in the presence of 10 nM IGF-1 using an antibody that
specifically recognizes the active MMP-2. Calreticulin is shown as a
loading control.
stimulated with IGF-1 for 8 hours. In each case, bands corresponding to
pro-MMP-2 and MMP-2 were quantified by densitometric analysis, and
their relations are represented in the bar graphs expressed in arbitrary
units. Bars denote the mean 6 SD from triplicate experiments. ns, non
significant. The asterisks show statistical differences with respect to
control for P < 0.05 (*).
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Having established a partial colocalization of MMP-2 and b1-
integrin in the periphery of the cell, and considering that FAK
is an important nonreceptor protein tyrosine kinase involved
in the cell–ECM adhesion,49 we next assessed the cellular
distribution of p-FAK (active form) and MMP-2 in human MGCs.
In the absence of IGF-1, p-FAK was concentrated at the edges
of the membrane ruffles (Fig. 7A, top), whereas under IGF-1
stimulus (8 hours) an intense staining was observed in small
foci within lamellipodia and filopodia (Fig. 7A, bottom). The
merged image for p-FAK/MMP-2 indicated that both proteins
partially colocalized in cellular protrusions (Fig. 7A, bottom).
The quantitative analysis showed that in perinuclear regions
the fluorescence of p-FAK and MMP-2 colocalization was
similar in control and IGF-1 stimulus (~4%) (Fig. 7B). By
contrast, in cellular protrusions the percentage of p-FAK/MMP-
2 colocalization was significantly increased (~12%) after IGF-1
treatment (Fig. 7B).
IGF-1 Induces the In Situ Proteolytic Activity
Concentrated Along F-Actin Filaments
Considering that IGF-1 induced a marked MMP-2 localization in
the cellular protrusions of MGCs, we next assessed whether
this MMP distribution correlated with an increased pericellular
proteolysis. To do this, in situ zymography assays containing
DQ-collagen as substrate were carried out as detailed in the
Materials and Methods section. With this substrate, both
gelatinase and collagenase activity of MMPs may be analyzed,
although other proteinases can also produce the proteolysis of
DQ-collagen substrate. Confocal microscopy analysis showed
that in the absence of IGF-1, the proteolytic activity was mainly
concentrated in perinuclear regions, and in some cells this
activity was weakly associated with cortical actin (Fig. 8A). By
contrast, MGCs stimulated with IGF-1 exhibited proteolytic
activity mainly distributed along the migration front in areas of
actin-rich filopodia and associated with cortical actin (Fig. 8B,
8C). Analysis at high-power magnification revealed that the
DQ-collagen proteolytic activity was oriented along actin
filaments in most cell filopodia of migrating MGCs. Our results
demonstrate that the accumulation of MMP-2 in cellular
protrusions was associated with an increased pericellular
proteolysis in MGCs stimulated with IGF-1.
DISCUSSION
IGF-1 is a polypeptide hormone that binds to its specific
receptor, IGF-1R, and exerts biological actions by activating
several intracellular signaling cascades, such as MAPK/ERK 1/2
and PI3K/AKT pathways.1,50 Several studies have shown that
these pathways may in fact be interdependent, as they exert
regulatory control on each other.33,51–53 Depending on the cell
type studied, the concentration, and the time course of the
IGF-1 stimulus, different effects in pericellular proteolytic
activity under physiological and pathologic processes have
been reported.54 To our knowledge, this is the first demon-
stration that IGF-1 in retina, through IGF-1R, decreases the
extracellular level of MMP-2 active form and induces MGC
migration. Considering that both IGF-1 effects were inhibited
by the pharmacologic inhibitor, LY294002, we conclude that
the PI3K/AKT pathway is involved in these extracellular and
migratory events of MGCs.
As previously described for other cell types, Western blot
analysis showed that after IGF-1R autophosphorylation, IGF-1
also induced the phosphorylation of AKT and ERK 1/2 in
MGCs. However, the PI3K/AKT pathway was differentially
activated because significant phosphorylated AKT levels were
observed at shorter times of IGF-1 stimulation compared with
the IGF-1 effect on phosphorylated ERK 1/2. In addition, the
pretreatment of MIO-M1 cells with the aI3R antibody inhibited
IGF-1R autophosphorylation as well as subsequent signaling
events, indicating that both signaling pathways were activated
by IGF-1 in retinal MGCs. In agreement with our observations,
various authors have previously identified IGF-1R as a regulator
of MMP-2 synthesis or activity via PI3K/AKT signaling pathway
in cancer cells.54,55 At the same time, Zhang and colleagues33
have demonstrated in a tumor cell model that low to moderate
levels of IGF-1 caused the activation of PI3K/AKT pathways,
which in turn inhibited the ERK pathway through AKT-
mediated Raf phosphorylation. High levels of stimulating IGF-
1 overcame this inhibition and led to ERK induction. The PI3K/
AKT pathway stimulated the MMP-2 expression, whereas the
Raf/MEK/ERK pathway was inhibitory. In our MGC model,
PI3K/AKT pathway activated by IGF-1 was also involved in
MMP-2 regulation evidenced by a reduction of the active form
at the extracellular level.
FIGURE 4. IGF-1 does not modify the MT1-MMP expression at cell
surface level. (A) Representative Western blot assay for the determi-
nation of MT1-MMP in MIO-M1 cells cultured in the presence of 10 nM
IGF-1 at indicated times. Calreticulin is shown as a loading control. The
bars represent the densitometric analysis of the immunoreactive
protein expressed as relative intensity calculated from the densitomet-
ric intensity of the MT1-MMP signal normalized to calreticulin. Bars
represent the mean 6 SD of three independent experiments. The
asterisks show statistical differences with respect to control for P <
0.001 (***). (B) Cells were treated (or not) with IGF-1 (10 nM) for 8
hours, and the cell surface level of MT1-MMP was evaluated by a biotin-
labeling protein assay and immunoblotted for MT1-MMP. Biotinylated
MT1-MMP: Represents the biotinylated-bound and eluted fraction of
the streptavidin-agarose beads. Total MT1-MMP: The input (10%) of
biotinylated proteins is shown. Actin was used as protein-loading
control.
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In normal cells, previous studies have also demonstrated
that PI3K activation causes the dedifferentiation of vascular
smooth muscle cells (VSMCs) and stimulates VSMC migration
by IGF-1-mediated MMP-2 upregulation.54 In the current study,
we showed by zymography that supernatants of MIO-M1 cells
treated with IGF-1 presented a significant reduction in the
active form of MMP-2 compared with untreated cells. In this
way, it was established that the migration of both normal and
cancer cells depended on MMP accumulation at membrane
protrusions, which is required for the focal pericellular
degradation of ECM.56 In line with this, we decided to evaluate
MMP-2 active expression by Western blot assays, using a
specific antibody that recognizes only the active form of this
MMP. Results revealed that IGF-1 produced an increased
accumulation of the active form of MMP-2 in MIO-M1 cells.
By a biotin-labeling cell surface protein assay, we can also
confirm that the amount of MT1-MMP at the cell surface was
not modified after IGF-1 stimulus. Hence, this particular
increase of MMP-2 in MIO-M1 would confer the focal
gelatinolytic activity necessary for supporting a migratory
phenotype.
It is known that in Col-I matrix, MT1-MMP initiates
denaturation of collagen into gelatin, which is subsequently
digested by MMP-2, facilitating pericellular proteolysis and
enhancing cell invasion and migration. Furthermore, it has
been suggested that the intracellular traffic of MT1-MMP
toward the cell surface and its participation in cellular
migration may be dependent on the tumoral or nontumoral
characteristics of cells, as well as on the presence of
extracellular factors that induce cellular migration, such as
Col-I57 and a2M,28 among others.44 Using two-dimensional
scratch wound assays, we demonstrated that, in fact, in the
FIGURE 5. IGF-1 induces MIO-M1 cell migration through its cognate receptor. (A) Representative two-dimensional scratch wound assay of MIO-M1
cells cultured in plates coated with collagen type I (collagen) in the presence or absence of IGF-1 (10 nM) during 12 hours. Scale bar: 100 lm. Bar
graph represents mean values 6 SD of the cell number invading the area of the wound (cells/area) in the absence (control) or presence of IGF-1 (10
nM) in plates coated with laminin or collagen. (B) Quantitative analysis of MIO-M1 cell migration by scratch wound assay of cells cultured in
collagen-coated plates pretreated with vehicle (C), aIR3 antibody (16 nM), GM6001 (20 lM), or LY-294002 (10 lM) for 30 minutes and then
stimulated with IGF-1 (10 nM) for 12 hours. Bar graph represents mean values 6 SD of the cell number invading the area of the wound (cells/area).
Three independent experiments were performed in triplicate. The asterisks show statistical differences with respect to control for P < 0.001 (***).
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absence of IGF-1 the cellular migration of MIO-M1 cells was
increased in the presence of Col-I with respect to laminin.
However, IGF-1 increased the migratory ability of MGC
independently from the ECM proteins used as cell support.
The blockade of IGF-1R autophosphorylation with aIR3
antibody inhibited the migratory process, which indicates that
IGF-1 is an extracellular factor inducing cell motility of MIO-M1
cells independently from the presence of Col-I per se.
Experiments performed with the synthetic MMP inhibitor
GM600158 revealed that this agent efficiently inhibits the
migration of MIO-M1 cells through inactivation of MMPs. In
addition, LY 294002 also decreased the MIO-M1 cell migration
in another set of scratch wound experiments. These results
clearly indicate that MIO-M1 cell migration requires the activity
of MMP-2 and PI3K/AKT signaling pathways.
In the present work, we observed that, under IGF-1
stimulus, MIO-M1 cells acquired migratory properties charac-
terized by the MMP-2 redistribution to cellular protrusions. In
this way, it was established that pericellular focalization of
proteolytic activity is required for adhesion and de-adhesion
processes that underlie cell motility.59 Previous work in cancer
cells have shown that membrane-linked MMP-2 is an important
element for tumor cell invasion through its link with
integrins.45,47 Herein, we showed that IGF-1 induced the
redistribution of MMP-2 in migrating cells. In these conditions,
a focalized peripheral distribution of MMP-2 across the cellular
protrusions replaced the pattern of distribution observed in
control cells, supporting the idea that MMP-2 is recruited to
specific areas at the leading edge of migrating MGCs. A similar
peripheral pattern was also observed for b-1 integrin and p-FAK
proteins under IGF-1 stimulus. It is known that the ligand
occupancy of different integrins regulates cell adhesion and
migration processes, which often involve formation of focal
adhesions.60–62 Here, the interactions of integrins with actin-
containing complexes led to activation of signaling events,
including phosphorylation of FAK. Integrins have been
implicated in cellular migrations in many contexts. These
include leukocyte trafficking in immune surveillance, move-
ments that mediate tissue regeneration and repair, and
migration during embryonic morphogenesis, among oth-
ers.63–65 Many human diseases, including retinopathies, have
been associated with altered integrin-mediated adhesion and
migration.66–68 Therefore, there has been strong interest in
understanding and potentially targeting integrin-mediated
FIGURE 6. b1-integrin and MMP-2 colocalization is increased in MIO-M1 cells stimulated with IGF-1. The top two rows show representative images
obtained by confocal microscopy. The MIO-M1 cells were cultured in glass coverslips coated with Col-I in the absence (control) or presence of IGF-1
(10 nM) for 8 hours. Then, b1-integrin was immunodetected using a polyclonal rabbit antibody, whereas for MMP-2 a mouse monoclonal antibody
was used. The overlaid images are magnifications of the protrusions (insets 1 and 2 or 1–3) of the cells (boxes) for b1-integrin and MMP-2 detection.
In masks 1 and 2 or 1, 2, and 3, b1-integrin and MMP-2 colocalizations are observed. Quantification of colocalization levels between b1-integrin and
MMP-2 was performed in cellular protrusions and perinuclear regions (PR) and is represented in the bar graph. Three independent experiments
were performed in triplicate. *P < 0.05 indicates statistical significance with respect to control. Scale bar: 20 lm.
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migration to treat human disease. Finally, actin cytoskeleton
organization and polymerization have a well-described role in
cell migration. Herein, we have also shown a gelatinase/
collagenase activity coincident with F-actin filaments in IGF-1-
treated cells. This finding is consistent with previous studies in
which the implication of MMPs in cell migration associated
with the actin cytoskeleton was shown in astrocytes and
olfactory ensheathing cells.48,69
Retinopathies have been classically considered to be
microcirculatory diseases; however, recent evidence indi-
cates that they are neurodegenerative retinal diseases.70 In
fact, a reduction of the fiber layer and neural apoptosis prior
to vascular complications has been described.71,72 At
present, treatments with antiangiogenic factors, laser pho-
tocoagulation, and surgical treatments can only delay loss of
vision in these patients, but in the long term, it is impossible
to prevent blindness. Taking this into account, the only hope
for restoration of sight is the development of stem cell–
based therapies to replace the damaged neurons that could
potentially integrate into the remaining neuronal network.
In the retina, under certain pathologic abnormalities, MGC
can undergo functional and phenotypic changes, thereby
acquiring the ability to migrate toward injured sites to
promote retinal remodeling and cellular repopulation.73,74
In addition, it has been demonstrated that the human-
derived MGC line, termed MIO-M1, exhibits stem cell
properties and may be used for neuronal regeneration
within mammalian retina.38,75 Although these transplanted
cells showed an acceptable integration, survival, and neural
differentiation in animal retinas with neurodegenerative
damage, the success of cellular therapy was relatively poor
due to the absence of migratory properties.74 Since the
regulatory mechanisms that promote this MGC migration are
unclear, it has been proposed that the stimulation of MIO-M1
cells with growth factors may induce the production or
regulation of MMP-2 and MMP-9, facilitating the cellular
migration of MGCs as well as the ECM remodeling.22,76
Interestingly, our results indicate that IGF-1, through its
receptor, may be an inducing factor of MGC migration, thus
facilitating cellular repopulation into the damaged host
retina. More studies, however, need to be done in order to
prove the migratory properties of this system in glial cells
during different retinal pathologies.
FIGURE 7. The p-FAK and MMP-2 colocalization is increased in MIO-M1 cells stimulated with IGF-1. The top two rows show representative images
obtained by confocal microscopy. MIO-M1 cells were cultured in glass coverslips coated with Col-I in the absence (control) or presence of IGF-1 (10
nM) for 8 hours. Then, p-FAK was immunodetected using a mouse monoclonal antibody, whereas for MMP-2 a rabbit monoclonal antibody was
used. The overlaid images are magnifications of the protrusions (insets 1–4) of the cells (boxes) for p-FAK and MMP-2 detection. In masks 1, 2, 3, and
4, p-FAK and MMP-2 colocalizations are observed (binary images). Quantification of colocalization levels between p-FAK and MMP-2 was performed
in the peripheral and PR and is represented in the bar graph. Three independent experiments were performed in triplicate. *P < 0.05 indicates
statistical significance with respect to control (C). Scale bar: 20 lm.
IGF-1 Regulates MMP-2 and Promotes MGC Motility IOVS j October 2015 j Vol. 56 j No. 11 j 6957
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/934564/ on 10/31/2015
Acknowledgments
We thank Gabriela Dı´az Cortez for her critical reading and language
revision of the manuscript. We also thank Maria Pilar Crespo for
confocal assistance and Fabricio Navarro for animal care.
Supported in part by Secretaria de Ciencia y Tecnolog´ıa-
Universidad Nacional de Co´rdoba (SECyT-UNC) N8 124/13 and
203/14; Fondo para la Investigacio´n Cient´ıfica y Tecnolo´gica
(FONCyT), Pre´stamo BID 2008 PICT N8 1642, PICT 2012 N8 2607,
and CONICET PIP 112-200801-02067.
Disclosure: V.E. Lorenc, None; J.R. Jaldı´n-Fincati, None; J.D.
Luna, None; G.A. Chiabrando, None; M.C. Sa´nchez, None
References
1. Laviola L, Natalicchio A, Giorgino F. The IGF-I signaling
pathway. Curr Pharm Des. 2007;13:663–669.
2. Dupont J, LeRoith D. Insulin and insulin-like growth factor I
receptors: similarities and differences in signal transduction.
Horm Res. 2001;55(suppl 2):22–26.
3. Bondy CA. Transient IGF-I gene expression during the
maturation of functionally related central projection neurons.
J Neurosci. 1991;11:3442–3455.
4. Lieskovska J, Ling Y, Badley-Clarke J, Clemmons DR. The role
of Src kinase in insulin-like growth factor-dependent mitogenic
signaling in vascular smooth muscle cells. J Biol Chem. 2006;
281:25041–25053.
5. Reinhardt RR, Bondy CA. Insulin-like growth factors cross the
blood-brain barrier. Endocrinology. 1994;135:1753–1761.
6. Wikstrand MH, Ha˚rd AL, Niklasson A, Hellstro¨m A. Birth
weight deviation and early postnatal growth are related to
optic nerve morphology at school age in children born
preterm. Pediatr Res. 2010;6:325–329.
7. Villacampa P, Haurigot V, Bosch F. Proliferative retinopathies:
animal models and therapeutic opportunities. Curr Neurovasc
Res. 2015;12:189–198.
8. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous
levels of the insulin-like growth factors I and II, and the insulin-
like growth factor binding proteins 2 and 3, increase in
neovascular eye disease. Studies in nondiabetic and diabetic
subjects. J Clin Invest. 1993;92:2620–2625.
9. Boulton M, Gregor Z, McLeod D, et al. Intravitreal growth
factors in proliferative diabetic retinopathy: correlation with
neovascular activity and glycaemic management. Br J Oph-
thalmol. 1997;81:228–233.
10. Waldbillig RJ, Jones BE, Schoen TJ, et al. Vitreal insulin-like
growth factor binding proteins (IGFBPs) are increased in
human and animal diabetics. Curr Eye Res. 1994;13:539–546.
11. Hellstrom A, Smith LE, Dammann O. Retinopathy of prema-
turity. Lancet. 2013;382:1445–1457.
12. Newman E, Reichenbach A. The Mu¨ller cell: a functional
element of the retina. Trends Neurosci. 1996;19:307–312.
13. Bringmann A, Pannicke T, Grosche J, et al. Mu¨ller cells in the
healthy and diseased retina. Prog Retin Eye Res. 2006;25:397–
424.
14. Reichenbach A, Stolzenburg JU, Eberhardt W, Chao TI,
Dettmer D, Hertz L. What do retinal Mu¨ller (glial) cells do
for their neuronal ‘‘small siblings’’? J Chem Neuroanat. 1993;
6:201–213.
15. Reichenbach A, Bringmann A. New functions of Mu¨ller cells.
Glia. 2013;61:651–678.
16. Morimoto T, Miyoshi T, Matsuda S, Tano Y, Fujikado T, Fukuda
Y. Transcorneal electrical stimulation rescues axotomized
retinal ganglion cells by activating endogenous retinal IGF-1
system. Invest Ophthalmol Vis Sci. 2005;46:2147–2155.
17. Sato T, Fujikado T, Morimoto T, Matsushita K, Harada T, Tano Y.
Effect of electrical stimulation on IGF-1 transcription by L-type
calcium channels in cultured retinal Mu¨ller cells. Jpn J
Ophthalmol. 2008;52:217–223.
18. Mizutani M, Gerhardinger C, Lorenzi M. Mu¨ller cell changes in
human diabetic retinopathy. Diabetes. 1998;47:445–449.
19. Feist RM Jr, King JL, Morris R, Witherspoon CD, Guidry C.
Myofibroblast and extracellular matrix origins in proliferative
vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 2014;
252:347–357.
20. Hiscott P, Sheridan C, Magee RM, Grierson I. Matrix and the
retinal pigment epithelium in proliferative retinal disease.
Prog Retin Eye Res. 1999;18:167–190.
21. Casaroli Marano RP, Preissner KT, Vilaro S. Fibronectin,
laminin, vitronectin and their receptors at newly-formed
capillaries in proliferative diabetic retinopathy. Exp Eye Res.
1995;60:5–17.
22. Limb GA, Daniels JT, Pleass R, Charteris DG, Luthert PJ, Khaw
PT. Differential expression of matrix metalloproteinases 2 and
9 by glial Mu¨ller cells: response to soluble and extracellular
matrix-bound tumor necrosis factor-alpha. Am J Pathol. 2002;
160:1847–1855.
FIGURE 8. IGF-1 induces increasing proteolytic activity concentrated
in the MGCs migrating front. (A–C) MGCs were cultured in glass
coverslips coated with Col-I in the absence (control) or presence of
IGF-1 (10 nM) and incubated for 6 hours in the presence of a collagen-
quenched fluorescent substrate that releases green fluorescence after
enzymatic cleavage by gelatinases/collagenases. The F-actin cytoskel-
eton was stained with Alexa Fluor 594 phalloidin. (A–C) show
representative images obtained by confocal microscopy. Insets (1–4)
are the enlargement of boxed areas at peripheral regions of cells shown
in (A–C). White arrowheads indicate codistribution of proteolytic
activity with F-actin in the migration front (A–C) and cortical F-actin (A,
B). Scale bar: 25 lm. Three independent experiments were performed
in triplicate.
IGF-1 Regulates MMP-2 and Promotes MGC Motility IOVS j October 2015 j Vol. 56 j No. 11 j 6958
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/934564/ on 10/31/2015
23. Miyata Y, Kase M, Sugita Y, et al. Protein kinase C-mediated
regulation of matrix metalloproteinase and tissue inhibitor of
metalloproteinase production in a human retinal Mu¨ller cells.
Curr Eye Res. 2012;37;842–849.
24. Limb GA, Little BC, Meager A, et al. Cytokines in proliferative
vitreoretinopathy. Eye (Lond). 1991;5(pt 6):686–693.
25. Franks WA, Limb GA, Stanford MR, et al. Cytokines in human
intraocular inflammation. Curr Eye Res. 1992;11(suppl):187–
191.
26. Limb GA, Alam A, Earley O, Green W, Chignell AH, Dumonde
DC. Distribution of cytokine proteins within epiretinal
membranes in proliferative vitreoretinopathy. Curr Eye Res.
1994;13:791–798.
27. Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC.
Distribution of TNF alpha and its reactive vascular adhesion
molecules in fibrovascular membranes of proliferative diabetic
retinopathy. Br J Ophthalmol. 1996;80:168–173.
28. Barcelona PF, Jald´ın-Fincati JR, Sa´nchez MC, Chiabrando GA.
Activated alpha2-macroglobulin induces Mu¨ller glial cell
migration by regulating MT1-MMP activity through LRP1.
FASEB J. 2013;27:3181–3197.
29. Chesik D, De Keyser J, Bron R, Fuhler GM. Insulin-like growth
factor binding protein-1 activates integrin-mediated intracellu-
lar signaling and migration in oligodendrocytes. J Neurochem.
2010;113:1319–1330.
30. Faber-Elman A, Solomon A, Abraham JA, Marikovsky M,
Schwartz M. Involvement of wound-associated factors in rat
brain astrocyte migratory response to axonal injury: in vitro
simulation. J Clin Invest. 1996;97:162–171.
31. Jiang J, McMurtry J, Niedzwiecki D, Goldman SA. Insulin-like
growth factor-1 is a radial cell-associated neurotrophin that
promotes neuronal recruitment from the adult songbird
edpendyma/subependyma. J Neurobiol. 1998;36:1–15.
32. Long L, Navab R, Brodt P. Regulation of the Mr 72,000 type IV
collagenase by the type I insulin-like growth factor receptor.
Cancer Res. 1998;58:3243–3247.
33. Zhang D, Bar-Eli M, Meloche S, Brodt P. Dual regulation of
MMP-2 expression by the type 1 insulin-like growth factor
receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK
pathways transmit opposing signals. J Biol Chem. 2004;279:
19683–19690.
34. Stetler-Stevenson WG. The role of matrix metalloproteinases
in tumor invasion, metastasis, and angiogenesis. Surg Oncol
Clin N Am. 2001;10:383–392, x.
35. Seiki M Yana I. Roles of pericellular proteolysis by membrane
type-1 matrix metalloproteinase in cancer invasion and
angiogenesis. Cancer Sci. 2003;94:569–574.
36. Sanchez MC, Luna JD, Barcelona PF, et al. Effect of retinal laser
photocoagulation on the activity of metalloproteinases and the
alpha(2)-macroglobulin proteolytic state in the vitreous of
eyes with proliferative diabetic retinopathy. Exp Eye Res.
2007;85:644–650.
37. Grant MB, Schmetz I, Russell B, Harwood HJ Jr, Silverstein J,
Merimee TJ. Changes in insulin-like growth factors I and II
and their binding protein after a single intramuscular
injection of growth hormone. J Clin Endocrinol Metab.
1986;63:981–984.
38. Limb GA, Salt TE, Munro PM, Moss SE, Khaw PT. In vitro
characterization of a spontaneously immortalized human
Mu¨ller cell line (MIO-M1). Invest Ophthalmol Vis Sci. 2002;
43:864–869.
39. Kleiner DE, Stetler-Stevenson, WG. Quantitative zymography:
detection of picogram quantities of gelatinases. Anal Bio-
chem. 1994;218:325–329.
40. Rivera S, Ogier C, Jourquin J, et al. Gelatinase B and TIMP-1 are
regulated in a cell- and time-dependent manner in association
with neuronal death and glial reactivity after global forebrain
ischemia. Eur J Neurosci. 2002;15:19–32.
41. Bolte S, Cordelieres, FP. A guided tour into subcellular
colocalization analysis in light microscopy. J Microsc. 2006;
224(pt 3):213–232.
42. Li YM, Schacher DH, Liu Q, et al. Regulation of myeloid
growth and differentiation by the insulin-like growth factor I
receptor. Endocrinology. 1997;138:362–368.
43. Strongin AY. Proteolytic and non-proteolytic roles of mem-
brane type-1 matrix metalloproteinase in malignancy. Biochim
Biophys Acta. 2010;1803:133–141.
44. Frittoli E, Palamidessi A, Disanza A, Scita G. Secretory and
endo/exocytic trafficking in invadopodia formation: the MT1-
MMP paradigm. Eur J Cell Biol. 2011;90:108–114.
45. Brooks PC, Stro¨mblad S, Sanders LC, et al. Localization of
matrix metalloproteinase MMP-2 to the surface of invasive
cells by interaction with integrin alpha v beta 3. Cell. 1996;85:
683–693.
46. Deryugina EI, Bourdon MA, Luo GX, Reisfeld RA, Strongin A.
Matrix metalloproteinase-2 activation modulates glioma cell
migration. J Cell Sci. 1997;110(pt 19):2473–2482.
47. Mitra A, Chakrabarti J, Chatterjee A. Binding of alpha5
monoclonal antibody to cell surface alpha5beta1 integrin
modulates MMP-2 and MMP-7 activity in B16F10 melanoma
cells. J Environ Pathol Toxicol Oncol. 2003;22:167–178.
48. Ogier C, Bernard A, Chollet AM, et al. Matrix metalloprotei-
nase-2 (MMP-2) regulates astrocyte motility in connection with
the actin cytoskeleton and integrins. Glia. 2006;54:272–284.
49. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in
command and control of cell motility. Nat Rev Mol Cell Biol.
2005;6:56–68.
50. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr.
Molecular and cellular aspects of the insulin-like growth factor
I receptor. Endocr Rev. 1995;16:143–163.
51. Lehman JA, Gomez-Cambronero J. Molecular crosstalk be-
tween p70S6k and MAPK cell signaling pathways. Biochem
Biophys Res Commun. 2002;293:463–469.
52. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M.
Regulation of Raf-Akt cross-talk. J Biol Chem. 2002;277:
31099–31106.
53. Zimmermann S, Moelling K. Phosphorylation and regulation of
Raf by Akt (protein kinase B). Science. 1999;286:1741–1744.
54. Risinger GM Jr, Hunt TS, Updike DL, Bullen EC, Howard EW.
Matrix metalloproteinase-2 expression by vascular smooth
muscle cells is mediated by both stimulatory and inhibitory
signals in response to growth factors. J Biol Chem. 2006;281:
25915–25925.
55. Stawowy P, Kallisch H, Kilimnik A, et al. Proprotein
convertases regulate insulin-like growth factor 1-induced
membrane-type 1 matrix metalloproteinase in VSMCs via
endoproteolytic activation of the insulin-like growth factor-1
receptor. Biochem Biophys Res Commun. 2004;321:31–538.
56. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM,
Mueller SC. Dynamic interactions of cortactin and membrane
type 1 matrix metalloproteinase at invadopodia: defining the
stages of invadopodia formation and function. Cancer Res.
2006;66:3034–3043.
57. Bravo-Cordero JJ, Marrero-Diaz R, Meg´ıas D, et al. MT1-MMP
proinvasive activity is regulated by a novel Rab8-dependent
exocytic pathway. EMBO J. 2007;26:1499–1510.
58. Galardy RE, Cassabonne ME, Giese C, et al. Low molecular
weight inhibitors in corneal ulceration. Ann N Y Acad Sci.
1994;732:315–323.
59. Sternlicht MD, Werb Z. How matrix metalloproteinases
regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:
463–516.
60. Huttenlocher A, Horwitz, AR. Integrins in cell migration. Cold
Spring Harb Perspect Biol. 2011;3:a005074.
IGF-1 Regulates MMP-2 and Promotes MGC Motility IOVS j October 2015 j Vol. 56 j No. 11 j 6959
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/934564/ on 10/31/2015
61. Wozniak MA, Modzelewska K, Kwong L, Keely PJ. Focal
adhesion regulation of cell behavior. Biochim Biophys Acta.
2004;1692:103–119.
62. Gleeson LM, Chakraborty C, McKinnon T, Lala PK. Insulin-like
growth factor-binding protein 1 stimulates human trophoblast
migration by signaling through alpha 5 beta 1 integrin via
mitogen-activated protein Kinase pathway. J Clin Endocrinol
Metab. 2001;86:2484–2493.
63. Webb DJ, Parsons JT, Horwitz AF. Adhesion assembly,
disassembly and turnover in migrating cells—over and over
and over again. Nat Cell Biol. 2002;4:E97–E100.
64. Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration:
integrating signals from front to back. Science. 2003;302:
1704–1709.
65. Friedl P, Wolf K. Plasticity of cell migration: a multiscale tuning
model. J Cell Biol. 2010;188:11–19.
66. Moreno-Layseca P, Streuli CH. Signalling pathways linking
integrins with cell cycle progression. Matrix Biol. 2014;34:
144–153.
67. Madamanchi A, Capozzi M, Geng L, et al. Mitigation of oxygen-
induced retinopathy in alpha2beta1 integrin-deficient mice.
Invest Ophthalmol Vis Sci. 2014;55:4338–4347.
68. Park SW, Yun JH, Kim JH, Kim KW, Cho CH, Kim JH.
Angiopoietin 2 induces pericyte apoptosis via alpha3beta1
integrin signaling in diabetic retinopathy. Diabetes. 2014;63:
3057–3068.
69. Gueye Y, Ferhat L, Sbai O, et al. Trafficking and secretion of
matrix metalloproteinase-2 in olfactory ensheathing glial cells:
A role in cell migration? Glia. 2011;59:750–770.
70. Barber AJ. A new view of diabetic retinopathy: a neurodegen-
erative disease of the eye. Prog Neuropsychopharmacol Biol
Psychiatry. 2003;27:283–290.
71. Barber AJ, Gardner TW, Abcouwer SF. The significance of
vascular and neural apoptosis to the pathology of diabetic
retinopathy. Invest Ophthalmol Vis Sci. 2011;52:1156–1163.
72. Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide
synthase mediates retinal apoptosis in ischemic proliferative
retinopathy. J Neurosci. 2002;22:3987–3993.
73. Romo P, Madigan MC, Provis JM, Cullen KM. Differential
effects of TGF-beta and FGF-2 on in vitro proliferation and
migration of primate retinal endothelial and Mu¨ller cells. Acta
Ophthalmol. 2011;89:e263–e268.
74. Bull ND, Limb GA, Martin KR. Human Mu¨ller stem cell (MIO-
M1) transplantation in a rat model of glaucoma: survival,
differentiation, and integration. Invest Ophthalmol Vis Sci.
2008;49:3449–3456.
75. Lawrence JM, Singhal S, Bhatia B, et al. MIO-M1 cells and
similar Mu¨ller glial cell lines derived from adult human retina
exhibit neural stem cell characteristics. Stem Cells. 2007;25:
2033–2043.
76. Tackenberg MA, Tucker BA, Swift JS, et al. Mu¨ller cell
activation, proliferation and migration following laser injury.
Mol Vis. 2009;15:1886–1896.
IGF-1 Regulates MMP-2 and Promotes MGC Motility IOVS j October 2015 j Vol. 56 j No. 11 j 6960
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/934564/ on 10/31/2015
